AIM: Brain metastasis was regarded, until recently, as a rare and late-stage event in patients with hepatocellular carcinoma (HCC). With the prolongation of survival in patients with advanced HCC by molecular targeted agents, this may have changed. We aimed to examine whether or not the incidence of brain metastasis in these patients has increased. METHODS: Between June 2005 and May 2009, 158 advanced HCC patients in total with either metastatic or locally advanced disease untreatable by locoregional therapies were enrolled in clinical trials of first-line antiangiogenic therapies. The clinicopathologic features and survival times of those who developed brain metastasis were analyzed. RESULTS: Eleven (7%) of 158 advanced HCC patients, with a median follow-up of 26.6 months, were diagnosed with brain metastasis as a result of compatible symptoms, confirmed by brain imaging. All 11 patients had extrahepatic metastasis upon enrollment, and 10 of them had lung metastasis. The median time to brain metastasis was 9.6 months (range, 0.6-19.6 months). The median overall survival (OS) time after diagnosis of brain metastasis was 4.6 months (range, 0.7-12.6 months). Four patients received brain tumor excision, and their survival duration after brain metastasis tended to be longer than that of those who did not (median OS time, 6.1 months versus 3.1 months). CONCLUSIONS: In the era of antiangiogenic targeted therapy, the importance of brain metastasis for advanced HCC patients may have increased.
AIM: Brain metastasis was regarded, until recently, as a rare and late-stage event in patients with hepatocellular carcinoma (HCC). With the prolongation of survival in patients with advanced HCC by molecular targeted agents, this may have changed. We aimed to examine whether or not the incidence of brain metastasis in these patients has increased. METHODS: Between June 2005 and May 2009, 158 advanced HCC patients in total with either metastatic or locally advanced disease untreatable by locoregional therapies were enrolled in clinical trials of first-line antiangiogenic therapies. The clinicopathologic features and survival times of those who developed brain metastasis were analyzed. RESULTS: Eleven (7%) of 158 advanced HCC patients, with a median follow-up of 26.6 months, were diagnosed with brain metastasis as a result of compatible symptoms, confirmed by brain imaging. All 11 patients had extrahepatic metastasis upon enrollment, and 10 of them had lung metastasis. The median time to brain metastasis was 9.6 months (range, 0.6-19.6 months). The median overall survival (OS) time after diagnosis of brain metastasis was 4.6 months (range, 0.7-12.6 months). Four patients received brain tumor excision, and their survival duration after brain metastasis tended to be longer than that of those who did not (median OS time, 6.1 months versus 3.1 months). CONCLUSIONS: In the era of antiangiogenic targeted therapy, the importance of brain metastasis for advanced HCC patients may have increased.
Authors: Mark L Sundermeyer; Neal J Meropol; Andre Rogatko; Hao Wang; Steven J Cohen Journal: Clin Colorectal Cancer Date: 2005-07 Impact factor: 4.481
Authors: F S Yen; J C Wu; C R Lai; W Y Sheng; B I Kuo; T Z Chen; S H Tsay; S D Lee Journal: J Gastroenterol Hepatol Date: 1995 Jul-Aug Impact factor: 4.029
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Seungtaek Lim; Soohyeon Lee; Jae Yun Lim; Ji Soo Park; Jin Sil Seong; Won Seok Chang; Kwang-Hyub Han; Hye Jin Choi Journal: J Neurooncol Date: 2014-07-26 Impact factor: 4.130
Authors: R A Pazo-Cid; M Lanzuela; G Esquerdo; J L Pérez-Gracia; A Antón; G Amigo; J Martínez Trufero; A L García-Otín; P Martín-Duque Journal: Clin Transl Oncol Date: 2012-07-18 Impact factor: 3.405
Authors: Mustafa S Ascha; Quinn T Ostrom; James Wright; Priya Kumthekar; Jeremy S Bordeaux; Andrew E Sloan; Fredrick R Schumacher; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-05 Impact factor: 4.254